Portfolio company Oxford Biodynamics (OBD) is a global biotech company, advancing personalised healthcare by developing and commercialising precision medicine tests for life-changing diseases using the proprietary EpiSwitch 3D genomics platform.
OBD announced it has been granted the US Foundation of NIH PACT Award for prognosis of cancer patients with IO-triggered Hyper-Progressive Disease, in recognition of its work in immune-oncology. The award, worth $963,000, will further fund development of the EpiSwitch platform and advance the work the Company is doing in cancer immunotherapy. This is the second time OBD has been recognised in this way by the US federal agencies and top pharmaceutical companies, and yet another validation of Oxford Biodynamics’ ability to address the clinical challenges presented by cancer treatment using its EpiSwitch platform.
Read more here: